Floatz logo

Eflornithine

Familial Adenomatous Polyposis

Cancer Prevention Pharmaceuticals, Inc.Small moleculePhase 3Dormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

11 Active assets in the Familial Adenomatous Polyposis cohort.

Asset / SponsorPhaseRating
Eicosapentanoic Acid
S.L.A. Pharma AG
Phase 3BB
Azithromycin
Tel-Aviv Sourasky Medical Center
Phase 4BB
Sulindac
Cancer Prevention Pharmaceuticals, Inc.
Phase 3BB
Erythromycin
michal roll
Phase 4BB
Dfn-15
Yonsei University
Phase 3BB

View all 27 →

Same molecule, other indications

Eflornithine is also rated in:

precancerous conditionDormant
BB
Indicative ·
64 / 100
View asset →
colon adenomaDormant
B
Indicative ·
57 / 100
View asset →
colorectal neoplasmDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →